Abstract
T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.
Current Molecular Medicine
Title:Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?
Volume: 12 Issue: 5
Author(s): I. Monteleone, M. Sarra, F. Pallone and G. Monteleone
Affiliation:
Abstract: T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.
Export Options
About this article
Cite this article as:
Monteleone I., Sarra M., Pallone F. and Monteleone G., Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?, Current Molecular Medicine 2012; 12(5) . https://dx.doi.org/10.2174/156652412800620066
DOI https://dx.doi.org/10.2174/156652412800620066 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Comparative Genomics for the Investigation of Autoimmune Diseases
Current Pharmaceutical Design Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Towards Improved Therapeutic CORMs: Understanding the Reactivity of CORM-3 with Proteins
Current Medicinal Chemistry Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Effect of Halofuginone on the Pathogenesis of Autoimmune Thyroid Disease in Different Mice Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design A Systematic Review of the Potential Herbal Sources of Future Drugs Effective in Oxidant-Related Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design